GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Cyclically Adjusted Book per Share

Biogen (BSP:BIIB34) Cyclically Adjusted Book per Share : R$67.15 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Biogen Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biogen's adjusted book value per share for the three months ended in Mar. 2024 was R$86.849. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$67.15 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biogen's average Cyclically Adjusted Book Growth Rate was 11.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 13.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 13.30% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Biogen was 61.50% per year. The lowest was 3.70% per year. And the median was 13.50% per year.

As of today (2024-05-23), Biogen's current stock price is R$171.36. Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was R$67.15. Biogen's Cyclically Adjusted PB Ratio of today is 2.55.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 16.44. The lowest was 2.41. And the median was 7.40.


Biogen Cyclically Adjusted Book per Share Historical Data

The historical data trend for Biogen's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted Book per Share Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.62 45.61 56.35 60.62 61.72

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.03 59.96 61.66 61.72 67.15

Competitive Comparison of Biogen's Cyclically Adjusted Book per Share

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PB Ratio falls into.



Biogen Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=86.849/131.7762*131.7762
=86.849

Current CPI (Mar. 2024) = 131.7762.

Biogen Quarterly Data

Book Value per Share CPI Adj_Book
201406 15.029 100.560 19.694
201409 17.137 100.428 22.486
201412 20.209 99.070 26.881
201503 25.864 99.621 34.212
201506 27.615 100.684 36.143
201509 30.733 100.392 40.341
201512 27.622 99.792 36.475
201603 28.940 100.470 37.957
201606 29.576 101.688 38.327
201609 30.076 101.861 38.909
201612 31.293 101.863 40.483
201703 27.848 102.862 35.676
201706 29.974 103.349 38.219
201709 31.622 104.136 40.015
201712 32.618 104.011 41.325
201803 36.253 105.290 45.373
201806 38.101 106.317 47.225
201809 46.602 106.507 57.659
201812 42.626 105.998 52.992
201903 45.171 107.251 55.501
201906 44.862 108.070 54.703
201909 52.617 108.329 64.005
201912 52.189 108.420 63.432
202003 60.830 108.902 73.607
202006 61.528 108.767 74.544
202009 62.664 109.815 75.196
202012 59.962 109.897 71.900
202103 66.351 111.754 78.238
202106 60.194 114.631 69.197
202109 62.218 115.734 70.842
202112 69.581 117.630 77.949
202203 62.963 121.301 68.400
202206 68.514 125.017 72.218
202209 77.224 125.227 81.263
202212 81.014 125.222 85.254
202303 82.382 127.348 85.247
202306 80.499 128.729 82.405
202309 81.947 129.860 83.157
202312 83.073 129.419 84.586
202403 86.849 131.776 86.849

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Biogen  (BSP:BIIB34) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biogen's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=171.36/67.15
=2.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 16.44. The lowest was 2.41. And the median was 7.40.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biogen Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BSP:BIIB34) Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BSP:BIIB34) Headlines

No Headlines